Mesoblast (ASX:MSB) said that its allogeneic cellular products will not be impacted by the US government's recently implemented tariffs on imported goods, according to a Friday filing with the Australian bourse.
The company clarified that these products are derived from US donors and are classified as US-origin, making them exempt from the tariffs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.